Skip to main content
Premium Trial:

Request an Annual Quote

Agencourt Meets GLP Compliance Guidelines

NEW YORK, June 30 - Agencourt Bioscience said today that an outside party has audited its facilities and confirmed them to be in compliance with the FDA's Good Laboratory Practices (GLP) guidelines.


Brendan McKernan, vice president of manufacturing and operations for Agencourt, told GenomeWeb that the genomic services firm brought in Omega PharmServices to benchmark its facilities against the FDA's 21 CFR part 58 regulations, which cover good laboratory practice for nonclinical laboratory studies.  


The GLP guidelines regulate quality assurance audits, preventive maintenance and training programs, sample tracking and laboratory information systems, and other analytical laboratory practices. "A lot of these things we've done for a number of years," said McKernan. "We just had to get an outside agency to say that we were actually compliant."


"This has really been driven by our customers," McKernan added. "They're looking to integrate the supply chain into guidelines that they have to follow from a regulatory standpoint."


McKernan said that all of Agencourt's current services have been deemed GLP compliant, and that the company expects to launch additional compliant product lines within the next several months.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.